•   employee termination costs incurred in 2018 as a result of initiatives to better align our organizational structure in europe.
•   employee termination costs incurred in 2017 as a result of (i) the acquisition of an irish biologic therapeutics company in the third quarter of 2017, (ii) initiatives to better align our organizational structure in europe, and (iii) our operational efficiency initiative and supply network strategy initiative; and
(f)   represents employee termination costs/(reversals) in europe as a result of initiatives to better align our organizational structure.